Phenylbutyrate (PB) acts as chemical chaperone and histone deacetylase inhibitor, which is used to decrease ammonia in urea cycle disorders and has been investigated for use in the treatment of a number of lethal illnesses. We performed in vivo and in vitro experiments to examine the effects of PB on glutamine (GLN), branchedchain amino acid (BCAA; valine, leucine and isoleucine) and protein metabolism in rats. In the first study, animals were sacrificed one hour after three injections of PB (300mg/kg b.w.) or saline. In the second study, soleus (SOL, slow twitch) and extensor digitorum longus (EDL, fast twitch) muscles were incubated in a medium with or without PB (5 mM). L-[1-14 C] leucine was used to estimate protein synthesis and leucine oxidation, and 3-methylhistidine release was used to evaluate myofibrillar protein breakdown. PB treatment decreased GLN, BCAA and branched-chain keto acids (BCKAs) in blood plasma, decreased BCAA and increased GLN concentrations in muscles, and increased GLN synthetase activities in muscles. Addition of PB to incubation medium increased leucine oxidation (55% in EDL, 29% in SOL), decreased BCKA and increased GLN in medium of both muscles, increased GLN in muscles, decreased protein synthesis in SOL and increased proteolysis in EDL. It is concluded that PB decreases BCAA, BCKA and GLN in blood plasma, activates BCAA catabolism and GLN synthesis in muscle and exerts adverse effects on protein metabolism. The results indicate that BCAA and GLN supplementation is needed when PB is used therapeutically and that PB may be a useful prospective agent which could be effective in management of maple syrup urine disease.
plasma in hepatectomized and laparotomized rats (Holecek & Vodenicarovova 2016) . Both GLN and BCAA act as anabolic agents and play important role in many processes including cell proliferation, expression of genes, and hormone production. Thus one could suppose that PB treatment could result in severe deficiency of GLN and BCAA, which may worsen the course of the illness, particularly via suppression of immune functions, impaired gut integrity and altered protein metabolism in skeletal muscle.
The first aim of this study was to assess the effect of PB treatment on GLN and BCAA concentrations in blood plasma and muscles. The second aim was to examine the effects of PB on GLN, BCAA and protein metabolism in two types of skeletal muscle of different metabolic properties -soleus (SOL, slow-twitch, red muscle) and extensor digitorum longus (EDL, fast-twitch, white muscle). The studies were performed both under in vivo and in vitro conditions to examine if the observed effects of PB are mediated directly or indirectly.
Materials and methods

Animals and material
Male Wistar rats (BioTest, Konarovice, CR) were housed in standardized cages in quarters with controlled temperature and a 12-h light-dark cycle. Rats were maintained on a ST-1 (Velas, CR) standard laboratory diet containing (w/w) 24% of nitrogenous compounds, 4% fat, 70% carbohydrates and 2% of minerals and vitamins, and drinking water ad libitum.
Sodium 4-phenylbutyrate (PB) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Chemicals were obtained from Sigma Chemical (St. Louis, MO, USA), Lachema (Brno, CR), Waters (Milford, MA, USA), Biomol (Hamburg, Germany) and Merck (Darmstadt, Germany).
Ethical approval statement
The Animal Care and Use Committee of Charles University, Faculty of Medicine in Hradec Kralove specifically approved this study (Licence No. 144879/2011-MZE-17214) . All applicable international, national, local and/or institutional guidelines governing the use of experimental animals were followed. Animals were treated carefully by animal experts educated and trained on how to manipulate animals to maintain a healthy environment and to reduce distress and minimize potential pain and suffering.
Experimental design and methods
Two series of experiments have been performed: the first under in vivo conditions and the second under in vitro conditions.
Study 1. Effects of PB under in vivo conditions
Rats weighing approximately 250 g each received three consecutive intraperitoneal injections of PB (300 mg/kg b.w.) or saline at 12-h intervals (Davies et al. 2009 ). To exclude nutritional effects, rats fasted during the study. The animals were sacrificed 1 h after the last injection in pentobarbital narcosis by exsanguination from the abdominal aorta. Blood was collected in heparinized tubes and immediately centrifuged for 10 min at 2000 9 g using a refrigerated centrifuge, and blood plasma was transferred into clean polypropylene tubes using a Pasteur pipette. Afterwards, small pieces (approximately 0.1 g) of soleus (SOL) and extensor digitorum longus (EDL) muscles were quickly removed and frozen in liquid nitrogen.
Amino acid concentrations. Amino acid concentrations were determined in supernatants of deproteinized samples of blood plasma, SOL, and EDL by liquid chromatography (Alliance 2695, Waters, Milford, MA, USA) after derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl carbamate (Waters, Milford, MA, USA) using norleucine as internal standard. The intracellular concentration of each amino acid was calculated by subtracting the free extracellular part from the total amount assuming the plasma concentration to be equal to the concentration in the interstitial fluid as described by Bergstr€ om et al. (1974) . Total tissue water was measured from the tissue weight obtained after drying for 24 h at 90°C. The determination of extra-and intracellular water was based on the chloride method according to Graham et al. (1967) .
Branched-chain keto acid (BCKA) concentrations. The reversed-phase HPLC combined with o-phenylenediamine derivatization was used for determination of BCKA in samples of blood plasma and incubation medium. Samples were pH-adjusted with 6 M sodium acetate (pH 6.0) prior to the chromatographic analysis. Keto acids were separated on LichroCart 125 9 4 mm, Purospher Star RP-18 (5 lm) endcapped analytical column (Merck Millipore, Darmstadt Germany) using mobile phase consisting of methanol and water at flow rate 0.8 ml/min in a gradient mode. The quinoxalinol derivatives of BCKAs were detected using fluorescence with emission and excitation at 410 nm and 350 nm, respectively, and quantified by internal standard method.
Glutamine synthetase activity. Glutamine synthetase activities in muscles were determined using a colorimetric assay based on the formation of c-glutamyl-hydroxamate (Minet et al. 1997) . Tissue samples were homogenized in imidazole buffer (pH 6.8, 0°C) with excess of GLN and hydroxylamine (1/9 w/v) and incubated at 37°C for 30 min. After centrifugation, the colour created by reaction with ferric chloride was measured at 530 nm in Tecan Infinite M200 spectrophotometer (Tecan Group Ltd., Switzerland). The results were expressed as relative units obtained by normalizing of the glutamine synthetase activity for control of SOL (A SOL = 1).
Study 2. Effects of PB on muscle under in vitro conditions
Animals weighing approximately 50 g were sacrificed in pentobarbital narcosis (6 mg/100 g body weight,
International Journal of Experimental Pathology, 2017, 98, 127-133 intraperitoneally) by exsanguination via abdominal aorta. SOL and EDL muscles of both legs were dissected according to Maizels et al. (1977) . Young animals weighing less than 75 g must be used to obtain muscles for in vitro experiments to avoid metabolic changes attributable to inadequate diffusion of gases and metabolites between the tissue and the medium (Maizels et al. 1977) . Muscles were fixed via the tendons to stainless steel clips to provide slight tension (at approximately resting length) and immediately transferred into 2. (Safranek et al. 2003a,b) . SOL and EDL of the right leg were used for determination of the effect of PB, and muscles of the left leg served as paired controls. The muscles were pre-incubated for 30 min in a thermostatically controlled bath (37°C) with a shaking device (70 cycles/ min) to ensure stable intramuscular concentrations of components present in the medium. After the pre-incubation, the muscles were quickly rinsed in 0.9% saline solution, blotted and transferred to a second set of vials and incubated in a medium containing 5 mM PB or in the same medium without PB. Concentration of PB in medium was based on the study of Carducci et al. (1996) who observed induction of apoptosis in human prostate cancer cells. Other components present in the medium were dependent on the parameter measured as described below.
Leucine oxidation and protein synthesis in muscles (in vitro study). Leucine oxidation and protein synthesis were determined using L-[1À 14 C]leucine as previously described in detail (Safranek et al. 2003a,b) . Leucine oxidation rates were calculated using the radioactivity of released 14 CO 2 , efficiency of 14 CO 2 recovery and leucine-specific activity in the incubation medium. The results were expressed as nmol of oxidized leucine/mg muscle protein per hour. Protein synthesis rates were calculated using the radioactivity of leucine incorporated in muscle protein and leucine-specific activity in the incubation medium. The results were expressed as nmol of incorporated leucine/mg protein per hour. The protein content was measured according to Lowry et al. (1951) .
3-Methylhistidine
(3-MH) release into incubation medium. Concentration of 3-MH, a characteristic product of the myofibrillar breakdown, in incubation medium was quantified using a high-performance liquid chromatography method (Alliance 2695, Waters, Milford, MA, USA) based on the reaction with fluorescamine. The release of 3-MH from incubated muscles was calculated on the basis of its concentrations in medium after two hours of the incubation, the volume of the medium and the weight of the muscle. Results were expressed as nmol/g wet muscle per hour.
Statistical analysis
The results are expressed as meanAESE. F-test followed by unpaired t-test (to estimate the effect of PB under in vivo conditions) and by paired t-test (to estimate the effect of PB on paired muscles from the same animal under in vitro condition) has been used for analysis of the data. Differences were considered significant at P ˂ 0.05. Statistical software NCSS 2001 (Kaysville, UT, USA) was applied for analysis.
Results
Effects of PB on GLN and BCAA concentrations (study in vivo) PB treatment decreased GLN and BCAA, that is valine, isoleucine and leucine concentrations in blood plasma. The Figure 1 Effects of PB on GLN and BCAA concentrations in blood plasma and in SOL and EDL muscles. Means AE SE of 10 animals, *P ˂ 0.05. Amino acid concentrations are given in lmol/l of blood plasma or mmol/l of intracellular fluid.
International Journal of Experimental Pathology, 2017, 98, 127-133 decrease in the BCAA in blood plasma was more significant than the decrease in GLN and was found also in muscles while GLN concentration in muscles increased (Figure 1) . The alterations in GLN and BCAA levels resulted in a marked increase in GLN to BCAA ratios both in blood plasma and muscles (Figure 2 ).
Effects of PB on GLN and BCAA concentrations in incubation medium and in incubated muscles (study in vitro)
Addition of PB into incubation medium increased GLN and decreased BCAA concentrations in medium with EDL and increased GLN to BCAA ratio in medium of both muscles. The effect of PB of GLN concentration in Figure 2 Effects of PB on GLN to BCAA ratio in blood plasma and muscles. Means AE SE of 10 animals, *P ˂ 0.05. incubation medium with SOL was insignificant ( Table 1) . Addition of PB into medium increased GLN concentrations in both muscles and GLN/BCAA in EDL. The effect of PB on intramuscular concentrations of the BCAA was insignificant ( Table 2) .
Effects of PB on leucine oxidation and protein metabolism in skeletal muscle (study in vitro)
Addition of PB to incubation medium increased leucine oxidation in both muscle types, decreased protein synthesis in SOL and enhanced protein breakdown in EDL (Figure 3) . The rise in leucine oxidation was more pronounced in EDL (55%) than in SOL (29%).
Effects of PB on BCKA concentrations
A marked decrease in all three BCKAs was found in blood plasma of PB-treated animals ( Figure 4 ) and in incubation medium containing PB (Table 3) . Figure 5 shows that glutamine synthetase activity was higher in EDL compared with SOL and that PB treatment increased glutamine synthetase activity in both muscle types.
Effects of PB on GLN synthesis in muscles
Discussion
Studies demonstrate that GLN deficiency impairs immune functions, gut integrity and protein balance in skeletal muscle (Buchman 1999; Exner et al. 2002; Hardy & Hardy 2008; Holecek & Sispera 2014) . The BCAA are essential amino acids, which serve as an essential substrate and regulator in protein synthesis (Tischler et al. 1982; Kimball & Jefferson 2001; Nair & Short 2005) . Therefore, the decrease in GLN and BCAA levels after PB administration may lead to various adverse effects on the body, which may have disastrous consequences particularly in patients with severe illness, in which GLN concentrations in blood plasma are Figure 4 Effects of PB on BCKA concentrations in blood plasma. Mean AE SE of 10 animals, *P ˂ 0.05. frequently low and BCAA catabolism is activated (Holecek et al. 1997; Exner et al. 2002; Hardy & Hardy 2008) .
While the decrease in GLN in blood plasma of PB-treated animals is undoubtedly due to the formation of phenylacetyl-GLN and its elimination by the urine, the mechanism causing the decrease in the BCAA is not completely clear. One possibility is that increased GLN disposal induces adaptive response characterized by enhanced consumption of BCAA for synthesis of glutamate that reacts with ammonia to GLN (Figure 6 ). This possibility has been confirmed in recent studies demonstrating that extracellular GLN deficiency enhances GLN release from muscle and activates BCAA catabolism while BCAA oxidation in muscles incubated in medium with high GLN concentration is inhibited (Holecek & Sispera 2014; Holecek et al. 2015) . However, increased GLN concentrations and leucine oxidation in muscles incubated with PB suggest that the cause of BCAA deficiency in blood and muscles after PB treatment is different.
An increase in leucine oxidation in muscles incubated in medium with PB indicates that PB activates the BCKA dehydrogenase, the rate-limiting enzyme of the BCAA oxidation. The consecutive increase in the BCAA oxidation should lead to the observed decrease in the BCAA in muscles and in blood. The explanation is supported by report of BrunettiPierri et al. (2011) , who demonstrated using liver extracts from PB-treated mice that PB enhances the proportion between active (unphosphorylated) and inactive (phosphorylated) form of the BCKA dehydrogenase by preventing phosphorylation of E1a subunit of the enzyme. It has been suggested that the stimulatory effect of PB on BCKA dehydrogenase activity may be used in treatment of maple syrup urine disease, a metabolic disorder caused by a deficiency of the BCKA dehydrogenase complex (Brunetti-Pierri et al. 2011) .
A consequence of activated oxidation of BCAA in muscles is the decrease in BCKA, which was observed both under in vivo (in blood plasma) and in vitro (in incubation medium) conditions. The BCKAs exert regulatory effects on protein metabolism in muscle, gluconeogenesis and ureagenesis in hepatocytes, insulin and glucagon release, act as an important source of energy and/or are reaminated to the BCAA (Tischler et al. 1982; Walser 1984; Holecek et al. 1998; Holecek 2001) . However, the effects of decreased BCKA levels on the body are obscure.
Enhanced catabolism of the BCAA in muscle is connected with enhanced production of glutamate (Figure 6 ), which may be amidated by glutamine synthetase to GLN. Glutamine synthetase is regulated by a number of variables, including its substrates and products (Stadtman 2001) , and it may be supposed that enhanced glutamate production and lack of feedback inhibition by end products of GLN metabolism due to enhanced GLN withdrawal as phenacetylglutamine have a role in activation of glutamine synthetase in PB-treated animals. Nevertheless, a direct effect of PB on glutamine synthetase activity cannot be excluded.
Increased oxidation of the BCAA and GLN synthesis in muscles may have adverse effects both on protein synthesis and proteolysis. The inhibitory effect of PB on protein synthesis was more pronounced in SOL while proteolysis increased significantly in EDL. In this connection, it should be noted that the effects of PB on leucine oxidation and GLN concentration in muscles were more pronounced in EDL and the decrease in BCAA concentrations in incubation medium after addition of PB was observed only in medium with EDL. Some articles indicate associations between BCAA and protein metabolism in muscle (O'Donnel et al. 1976; Holecek 2011) and, therefore, the differences in BCAA and GLN metabolism induced by PB in SOL and EDL may play a role in different alterations in protein metabolism. The findings of more pronounced effects of PB in EDL (composed predominantly of white, fast-twitch fibres) compared with SOL (composed predominantly of red, slowtwitch fibres) is a further evidence of higher sensitivity of fast-twitch fibres to various signals than slow-twitch fibres as reported in number of other articles (Kadlcikova et al. 2004; Muthny et al. 2008 Muthny et al. , 2009 ).
In conclusion, to the best of our knowledge, this is the first study reporting that PB treatment decreases BCAA and BCKA levels and increases BCAA oxidation and GLN synthesis in skeletal muscle. These effects may exert adverse effects on protein balance in skeletal muscle and the course of the illness in which PB is used as a therapeutic agent. The results also indicate that BCAA and GLN supplementation is needed when PB is used therapeutically and that PB may be perspective in management of high concentrations of BCKA in maple syrup urine disease, a hereditary disease that is due to the lack of the BCKA dehydrogenase. Further studies are needed to examine the effects of chronical administration of PB on amino acid concentrations and protein balance.
